Streptozocin (Zanosar) Oncology Medication Facing Ongoing Supply Shortage
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA reports a current shortage of Streptozocin Powder for Solution, with Teva Pharmaceuticals reporting the medication as currently unavailable.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 6, 2026 and geographically references United States. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Streptozocin.
What's in Shortage
Streptozocin Powder, For Solution (Brand name: Zanosar) is currently in shortage. This medication is classified under the therapeutic category of Oncology. The shortage affects the 100 mg/1 mL presentation (NDC 0703-4636-01).
Which Manufacturers Are Affected
Currently, Teva Pharmaceuticals USA, Inc. is the manufacturer listed with availability issues:
- Status: Unavailable
- Presentation: Zanosar, Powder, For Solution, 100 mg/1 mL (NDC 0703-4636-01)
- Estimated Recovery: To Be Determined (TBD)
- Contact Information: 800-545-8800
Why There's a Shortage
The reason for the shortage provided to the FDA is listed as "Other." No specific details regarding manufacturing delays or supply chain issues were disclosed.
What Patients Should Do
Patients who are currently prescribed Streptozocin for oncology treatment should take the following steps:
- Consult Your Healthcare Provider: Speak with your oncologist or primary physician immediately to discuss your treatment plan and potential alternatives.
- Contact Your Pharmacist: Check with your pharmacy regarding their current stock and potential lead times for new shipments.
- Contact the Manufacturer: You may reach out to Teva Pharmaceuticals at 800-545-8800 for the most recent updates on their supply status.
Disclaimer: Patients should consult their healthcare provider for all medical advice, diagnosis, and treatment options. Do not make changes to your medication regimen without professional medical guidance.
Source
Information provided by the FDA Drug Shortage Database.
- Initial Posting Date: 07/12/2022
- Last Updated: 02/02/2026
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.